The presentation of positive data from Pliant Therapeutics' Bexotegrast program at the EASL International Liver Congress demonstrates the potential of the drug in treating liver fibrosis. This could lead to increased investor confidence in the company's pipeline, potentially driving the stock price up in the short term.